Outcomes of Bioprosthetic Valves in the Pulmonary Position in Adults With Congenital Heart Disease

Alexander C. Egbe, Heidi M. Connolly, William R. Miranda, Joseph A. Dearani, Hartzell V. Schaff

Research output: Contribution to journalArticle

Abstract

Background: There are limited data on the incidence of prosthetic valve dysfunction (PVD) after pulmonary valve replacement (PVR). The purpose of this study was to determine the longevity of bioprosthetic valves in the pulmonary position and the factors associated with bioprosthetic valve longevity in adults with congenital heart disease. Methods: This retrospective review of adults with bioprosthetic PVR was conducted at the Mayo Clinic in Rochester, Minnesota from 1990 to 2017. The study end point was PVD, defined as peak velocity greater than 4 m/s, severe prosthetic regurgitation, or both. For the purpose of this study we assessed bioprosthetic valve longevity by using 3 different indices: (1) cumulative incidence of PVD, (2) incidence density of PVD, and (3) time to PVD. Results: There were 807 bioprosthetic PVRs in 573 patients. PVD occurred in 267 (33%) prostheses. Time to PVD was 12.6 ± 3.9 years, the incidence of PVD was 3.2 (95% confidence interval [CI], 3.0 to 3.4) cases per 100 prosthesis-years, and the 15-year cumulative incidence was 48% (95% CI, 43%- to 53%). No difference in prosthesis longevity by type of prosthesis implanted was observed. The multivariate risk factors for PVD were a history of atrial fibrillation (hazard ratio [HR], 1.36; 95% CI, 1.08 to 2.54; P = .014), and greater than moderate right ventricular dysfunction (HR, 1.21, 95% CI, 1.01 to 1.48; P = .049). Postoperative anticoagulation with a vitamin K antagonist was associated with a lower risk of PVD (HR, 0.83; 95% CI, 0.61 to 0.92; P = .038). Conclusions: The limited longevity of bioprosthetic valves poses significant concerns about the cumulative lifetime risk of reinterventions. Prospective studies are required to determine if interventions such as treatment of atrial fibrillation and postoperative anticoagulation will delay the occurrence of PVD.

Original languageEnglish (US)
Pages (from-to)1410-1415
Number of pages6
JournalAnnals of Thoracic Surgery
Volume108
Issue number5
DOIs
StatePublished - Nov 2019

Fingerprint

Pulmonary Valve
Heart Diseases
Prostheses and Implants
Confidence Intervals
Incidence
Atrial Fibrillation
Right Ventricular Dysfunction
Vitamin K
Prospective Studies

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Outcomes of Bioprosthetic Valves in the Pulmonary Position in Adults With Congenital Heart Disease. / Egbe, Alexander C.; Connolly, Heidi M.; Miranda, William R.; Dearani, Joseph A.; Schaff, Hartzell V.

In: Annals of Thoracic Surgery, Vol. 108, No. 5, 11.2019, p. 1410-1415.

Research output: Contribution to journalArticle

Egbe, Alexander C. ; Connolly, Heidi M. ; Miranda, William R. ; Dearani, Joseph A. ; Schaff, Hartzell V. / Outcomes of Bioprosthetic Valves in the Pulmonary Position in Adults With Congenital Heart Disease. In: Annals of Thoracic Surgery. 2019 ; Vol. 108, No. 5. pp. 1410-1415.
@article{e3e32e871399487ea7e24ec343ab07e6,
title = "Outcomes of Bioprosthetic Valves in the Pulmonary Position in Adults With Congenital Heart Disease",
abstract = "Background: There are limited data on the incidence of prosthetic valve dysfunction (PVD) after pulmonary valve replacement (PVR). The purpose of this study was to determine the longevity of bioprosthetic valves in the pulmonary position and the factors associated with bioprosthetic valve longevity in adults with congenital heart disease. Methods: This retrospective review of adults with bioprosthetic PVR was conducted at the Mayo Clinic in Rochester, Minnesota from 1990 to 2017. The study end point was PVD, defined as peak velocity greater than 4 m/s, severe prosthetic regurgitation, or both. For the purpose of this study we assessed bioprosthetic valve longevity by using 3 different indices: (1) cumulative incidence of PVD, (2) incidence density of PVD, and (3) time to PVD. Results: There were 807 bioprosthetic PVRs in 573 patients. PVD occurred in 267 (33{\%}) prostheses. Time to PVD was 12.6 ± 3.9 years, the incidence of PVD was 3.2 (95{\%} confidence interval [CI], 3.0 to 3.4) cases per 100 prosthesis-years, and the 15-year cumulative incidence was 48{\%} (95{\%} CI, 43{\%}- to 53{\%}). No difference in prosthesis longevity by type of prosthesis implanted was observed. The multivariate risk factors for PVD were a history of atrial fibrillation (hazard ratio [HR], 1.36; 95{\%} CI, 1.08 to 2.54; P = .014), and greater than moderate right ventricular dysfunction (HR, 1.21, 95{\%} CI, 1.01 to 1.48; P = .049). Postoperative anticoagulation with a vitamin K antagonist was associated with a lower risk of PVD (HR, 0.83; 95{\%} CI, 0.61 to 0.92; P = .038). Conclusions: The limited longevity of bioprosthetic valves poses significant concerns about the cumulative lifetime risk of reinterventions. Prospective studies are required to determine if interventions such as treatment of atrial fibrillation and postoperative anticoagulation will delay the occurrence of PVD.",
author = "Egbe, {Alexander C.} and Connolly, {Heidi M.} and Miranda, {William R.} and Dearani, {Joseph A.} and Schaff, {Hartzell V.}",
year = "2019",
month = "11",
doi = "10.1016/j.athoracsur.2019.05.068",
language = "English (US)",
volume = "108",
pages = "1410--1415",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Outcomes of Bioprosthetic Valves in the Pulmonary Position in Adults With Congenital Heart Disease

AU - Egbe, Alexander C.

AU - Connolly, Heidi M.

AU - Miranda, William R.

AU - Dearani, Joseph A.

AU - Schaff, Hartzell V.

PY - 2019/11

Y1 - 2019/11

N2 - Background: There are limited data on the incidence of prosthetic valve dysfunction (PVD) after pulmonary valve replacement (PVR). The purpose of this study was to determine the longevity of bioprosthetic valves in the pulmonary position and the factors associated with bioprosthetic valve longevity in adults with congenital heart disease. Methods: This retrospective review of adults with bioprosthetic PVR was conducted at the Mayo Clinic in Rochester, Minnesota from 1990 to 2017. The study end point was PVD, defined as peak velocity greater than 4 m/s, severe prosthetic regurgitation, or both. For the purpose of this study we assessed bioprosthetic valve longevity by using 3 different indices: (1) cumulative incidence of PVD, (2) incidence density of PVD, and (3) time to PVD. Results: There were 807 bioprosthetic PVRs in 573 patients. PVD occurred in 267 (33%) prostheses. Time to PVD was 12.6 ± 3.9 years, the incidence of PVD was 3.2 (95% confidence interval [CI], 3.0 to 3.4) cases per 100 prosthesis-years, and the 15-year cumulative incidence was 48% (95% CI, 43%- to 53%). No difference in prosthesis longevity by type of prosthesis implanted was observed. The multivariate risk factors for PVD were a history of atrial fibrillation (hazard ratio [HR], 1.36; 95% CI, 1.08 to 2.54; P = .014), and greater than moderate right ventricular dysfunction (HR, 1.21, 95% CI, 1.01 to 1.48; P = .049). Postoperative anticoagulation with a vitamin K antagonist was associated with a lower risk of PVD (HR, 0.83; 95% CI, 0.61 to 0.92; P = .038). Conclusions: The limited longevity of bioprosthetic valves poses significant concerns about the cumulative lifetime risk of reinterventions. Prospective studies are required to determine if interventions such as treatment of atrial fibrillation and postoperative anticoagulation will delay the occurrence of PVD.

AB - Background: There are limited data on the incidence of prosthetic valve dysfunction (PVD) after pulmonary valve replacement (PVR). The purpose of this study was to determine the longevity of bioprosthetic valves in the pulmonary position and the factors associated with bioprosthetic valve longevity in adults with congenital heart disease. Methods: This retrospective review of adults with bioprosthetic PVR was conducted at the Mayo Clinic in Rochester, Minnesota from 1990 to 2017. The study end point was PVD, defined as peak velocity greater than 4 m/s, severe prosthetic regurgitation, or both. For the purpose of this study we assessed bioprosthetic valve longevity by using 3 different indices: (1) cumulative incidence of PVD, (2) incidence density of PVD, and (3) time to PVD. Results: There were 807 bioprosthetic PVRs in 573 patients. PVD occurred in 267 (33%) prostheses. Time to PVD was 12.6 ± 3.9 years, the incidence of PVD was 3.2 (95% confidence interval [CI], 3.0 to 3.4) cases per 100 prosthesis-years, and the 15-year cumulative incidence was 48% (95% CI, 43%- to 53%). No difference in prosthesis longevity by type of prosthesis implanted was observed. The multivariate risk factors for PVD were a history of atrial fibrillation (hazard ratio [HR], 1.36; 95% CI, 1.08 to 2.54; P = .014), and greater than moderate right ventricular dysfunction (HR, 1.21, 95% CI, 1.01 to 1.48; P = .049). Postoperative anticoagulation with a vitamin K antagonist was associated with a lower risk of PVD (HR, 0.83; 95% CI, 0.61 to 0.92; P = .038). Conclusions: The limited longevity of bioprosthetic valves poses significant concerns about the cumulative lifetime risk of reinterventions. Prospective studies are required to determine if interventions such as treatment of atrial fibrillation and postoperative anticoagulation will delay the occurrence of PVD.

UR - http://www.scopus.com/inward/record.url?scp=85072650105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072650105&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2019.05.068

DO - 10.1016/j.athoracsur.2019.05.068

M3 - Article

C2 - 31323213

AN - SCOPUS:85072650105

VL - 108

SP - 1410

EP - 1415

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -